Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18053620 | 0.94 | SIGMAR1 (0.45) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL14155850 | 0.94 | SIGMAR1 (0.51) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL4544710 | 0.91 | SIGMAR1 (0.54) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL20256063 | 0.91 | SIGMAR1 (0.54) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL4440912 | 0.89 | SIGMAR1 (0.47) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL13439372 | 0.86 | L3MBTL3 (0.42) | SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL12563384 | 0.85 | L3MBTL3 (0.39) | SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL11916112 | 0.84 | SIGMAR1 (0.42) | SIGMAR1TSHRGAANPSR1MEN1 | |
| SCHEMBL23718057 | 0.83 | L3MBTL3 (0.39) | SIGMAR1HTR6L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL117945 | 0.82 | SIGMAR1 (0.41) | SIGMAR1TSHRGAAL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | SIGMAR1 3795/4885TSHR 4105/4885GAA 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.